Tanezumab, identified by the catalog designation 880266-57-9, represents a monoclonal antibody solution demonstrating significant application in treating debilitating osteoarthritis pain. This humanized antibody specifically targets pain growth protein, blocking its effect and thereby reducing pain within affected areas . The clinical data surrounding 880266-57-9 highlights its power to offer substantial pain relief while perhaps limiting the requirement for conventional analgesics. Further studies are diligently underway to completely determine its long-term well-being and effectiveness 880266-57-9 .
Understanding Tanezumab's Role in Pain Management: An Immune Protein Outlook
Tanezumab, a groundbreaking therapeutic approach, offers a specific pathway in long-term pain alleviation. As a monoclonal antibody, it specifically targets and inhibits nerve development factor (NGF), a key molecule participating in sensory discomfort signaling. Unlike standard opioid medications, tanezumab’s protein mechanism allows for a focused specific action, arguably decreasing the risk of some common side reactions linked with generalized pain reduction. However, its protein nature necessitates a careful consideration of anticipated body's reactions and long-term consequences when utilized within a complete pain therapy plan.
Tanezumab Reagent (880266-57-9): Purity , Grade & Uses
The Tanezumab Solution with the identifier 880266-57-9 is a critical component in various research applications, particularly concerning joint pain treatment development. Achieving a high level of purity is paramount; therefore, rigorous testing protocols are employed to guarantee its appropriateness for intended use. Our production method focuses on maximizing cleanliness , employing sophisticated purification techniques to remove impurities . Typical specifications include a >95% purity level as determined by HPLC and comprehensive testing for biochemical integrity. The primary applications revolve around its role as a scientific resource for investigating the mechanisms of arthritis progression and developing novel therapeutic interventions .
- Research Investigations
- Therapeutic Development
- Mechanism Studies
The Investigation Behind Tanezumab: Analyzing the 880266-57-9 Antibody
Tanezumab, identified with the chemical identifier 880266-57-9, represents a novel biological antibody targeting pain-sensing development factor receptor (NGF). This mechanism of effect revolves upon precisely binding to NGF, consequently inhibiting its role and later communication transduction. Scientists have revealed that this biological molecule presents promise for managing severe pain, particularly linked to illnesses like osteoarthritis and chronic back pain. More research are underway to fully define its impact and safety characteristics.
New Progress in The Study: Focusing on the The Substance
Future studies surrounding tanezumab, a experimental therapeutic compound, are increasingly directed on characterizing the role of the identified reagent, compound 880266-57-9. This discovery and detailed evaluation of such biological entity suggests vital for optimizing the drug's effectiveness and reducing anticipated undesirable effects. Preliminary data suggest that 880266-57-9 functions a significant part in the therapy's process of action. Additional investigations will be needed to fully clarify this reagent's effect.
Tanezumab Antibody (880266-57-9): Production, Characteristics, and Potential
The production process of tanezumab, an humanized monoclonal antibody (identified by CAS number 880266-57-9), typically involves mammalian cell culture, often utilizing Chinese hamster ovary cells for high yield. Its primary characteristic is its ability to selectively target and degrade cathepsin-K, an enzyme crucial for bone resorption. This binding mechanism results in a significant reduction in osteoclast activity. The molecule exhibits a defined molecular weight and specific amino acid sequence, allowing for detailed characterization through techniques such as mass spectrometry and protein sequencing. Consequently, tanezumab’s potential lies in treating conditions characterized by excessive bone loss, like osteoarthritis and metastatic bone disease, although clinical development has been complex due to adverse event profiles and ongoing evaluation.}